Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631185 | 0.84 | DGAT1 (0.34) | DGAT1NPC1MAPT | |
| SCHEMBL31425717 | 0.83 | — | — | |
| SCHEMBL21608128 | 0.82 | — | — | |
| SCHEMBL15745940 | 0.81 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL15572246 | 0.80 | DGAT1 (0.40) | DGAT1NPC1MAPT | |
| SCHEMBL27334639 | 0.80 | MLYCD (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL15471725 | 0.79 | DGAT1 (0.41) | DGAT1NPC1MAPT | |
| SCHEMBL25586533 | 0.77 | DGAT1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL16397004 | 0.76 | NPC1 (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL30889433 | 0.75 | DGAT1 (0.37) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250129053-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-24 | — | — | US | disclosed |
| CN-119278038-A | T-type calcium channel modulators comprising piperazine or 1, 4-diazacycloheptane cores and methods of use thereof | 普拉西斯精密医药公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4419517-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | Syngenta Crop Protection AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-118103362-A | Herbicidal imidazole compounds | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023250157-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023066783-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| EP-4165035-A1 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | CACNA1G, CACNA1I, CACNA1H | DGAT1 1693/4885NPC1 887/4885MAPT 569/4885 |
| US-20250129053-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | DDT, H1-0, H1-3 | DGAT1 1915/4885NPC1 4152/4885MAPT 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.